Immunotech Biopharm (HKSE:06978) Shares Outstanding (EOP): 617.50 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
17 GF Score
Price HK$0.39
! 4 Warning Signs
View Full Analysis

What is Immunotech Biopharm Shares Outstanding (EOP)?

Immunotech Biopharm HKSE:06978 17 Shares Outstanding (EOP) is 617.50 Mil as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Immunotech Biopharm's shares outstanding for the quarter that ended in Dec. 2025 was 617.50 Mil.

Immunotech Biopharm's quarterly shares outstanding increased from Jun. 2025 (559.68 Mil) to Dec. 2025 (617.50 Mil). It means Immunotech Biopharm issued new shares from Jun. 2025 to Dec. 2025 .

Immunotech Biopharm's annual shares outstanding increased from Dec. 2024 (559.68 Mil) to Dec. 2025 (617.50 Mil). It means Immunotech Biopharm issued new shares from Dec. 2024 to Dec. 2025 .


Immunotech Biopharm  (HKSE:06978) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Immunotech Biopharm Shares Outstanding (EOP) Related Terms


Immunotech Biopharm Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Shares Outstanding (EOP) Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 559.68 559.68 559.68 559.68 617.50

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 559.68 559.68 559.68 559.68 617.50

HKSE:06978 vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Immunotech Biopharm's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Shares Outstanding (EOP) falls into.


HKSE:06978
17GF Score
Immunotech Biopharm Ltd HKSE:06978
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 617.50 Mil mean?
Immunotech Biopharm (HKSE:06978) has a Shares Outstanding (EOP) of 617.50 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Immunotech Biopharm and its competitors.
Is Immunotech Biopharm's Shares Outstanding (EOP) too high?
Immunotech Biopharm's current Shares Outstanding (EOP) is 617.50 Mil. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Shares Outstanding (EOP) compare to VRTX and REGN?
Immunotech Biopharm's Shares Outstanding (EOP) of 617.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current Shares Outstanding (EOP) is 617.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Shares Outstanding (EOP) of 617.50 Mil. The current Shares Outstanding (EOP) is 617.50 Mil. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Shares Outstanding (EOP) is 617.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score

Get the complete analysis for HKSE:06978

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.39
Price